Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer-Reference-Cited by-同舟云学术

Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer

Published:2017-10 Issue: Volume:190 Page:108-117
ISSN:0165-2478
Container-title:Immunology Letters
language:en
Short-container-title:Immunology Letters

Author:

Barati Nastaran,Nikpoor Amin Reza,Razazan Atefeh,Mosaffa Fatemeh,Badiee Ali,Arab Atefeh,Gholizadeh Zahra,Behravan Javad,Jaafari Mahmoud Reza

Funder

Mashhad University of Medical Sciences, Biotechnology Research Center and Nanotechnology Research Center

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference38 articles.

1. Grape juice concentrate prevents oxidative DNA damage in peripheral blood cells of rats subjected to a high-cholesterol diet;Aguiar;Br. J. Nutr.,2011

2. Eradication of established tumors by CD8+ T cell adoptive immunotherapy;Hanson;Immunity,2000

3. Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy;Matsui;Int. Immunol.,2003

4. Breast cancer: origins and evolution;Polyak;J. Clin. Invest.,2007

5. Reorganizing the protein space at the universal protein resource (UniProt);Consortium;Nucleic Acids Res.,2011

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug delivery methods for cancer immunotherapy;Drug Delivery and Translational Research;2023-08-16

2. Nanomaterials in Cancer Immunotherapy: A Spotlight on Breast Cancer;Science of Advanced Materials;2023-03-01

3. Nanoliposomes as safe and efficient drug delivery nanovesicles;Advanced and Modern Approaches for Drug Delivery;2023

4. Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches;Journal of Controlled Release;2022-09

5. Emerging advances in nanomedicine for breast cancer immunotherapy: opportunities and challenges;Immunotherapy;2022-08